Why the study?
Does aprotinin reduce thrombin formation and coagulation activation in patients undergoing cardiopulmonary bypass?
Does aprotinin reduce thrombin formation and coagulation activation in patients undergoing cardiopulmonary bypass?
Aprotinin reduces contact-phase activation during cardiopulmonary bypass, leading to decreased thrombin formation and lower heparin requirements.
No takes yet. Share an insight, caveat, or question.
May allow lower heparin dosing with aprotinin in CPB; leaves open clinical outcome effects pending prospective trials.
Wulf Dietrich (1996) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: